Fludeoxyglucose F-18
Brand Names: Fludeoxyglucose F18
Methodology & AI Transparency ⓘ
Fludeoxyglucose F-18 Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
- 2 Real-world patient consensus: Zero-PHI community consensus: 83% favorable across 16 logged regimens (Fludeoxyglucose F18).
- 3 Typical cash cost range: Public pharmacy ledger: $119.88 low cash benchmark vs. $293.71 chain retail average ($2.7500/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Fludeoxyglucose F-18 include cutaneous rash (3%), pruritus (3.3%), peripheral edema (3%).
Ask our AI Specialists anything about Fludeoxyglucose F-18
Fludeoxyglucose F-18 Mechanism, CYP450 Pathways & DailyMed Monograph
Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
12.1 Mechanism of Action Fludeoxyglucose F 18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase.
Following administration (300 mCi/mL Injection, Solution), Fludeoxyglucose F-18 achieves Complete (~100%) parenteral systemic delivery for Fludeoxyglucose F-18 (300 mCi/mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after fludeoxyglucose f-18 administration onset, governed by a 0.2-0.3 minutes terminal elimination (Fludeoxyglucose F-18 SPL) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar fludeoxyglucose f-18 conjugates.
Before initiating Fludeoxyglucose F-18 at 300 mCi/mL Injection, Solution, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to fludeoxyglucose f-18 (ndc 24450-647); severe baseline organ impairment where fludeoxyglucose f-18 accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (8.9% of reports), headache (8.4% of reports), dizziness (5.7% of reports).
Reconcile eGFR-adjusted medications before escalating Fludeoxyglucose F-18 in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Fludeoxyglucose F-18; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Fludeoxyglucose F-18 (NDC 24450-647)
- Severe baseline organ impairment where Fludeoxyglucose F-18 accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (16 Reports)
Fludeoxyglucose F-18 Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fludeoxyglucose F-18)
Human clinical trial evidence for Fludeoxyglucose F-18 is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Fludeoxyglucose F-18 Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.7500/unit (~$82.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $293.71 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $119.88 / mo | View logs ↓ |
Fludeoxyglucose F-18 Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fludeoxyglucose F-18 RxNorm Concept ID | RXN-24450647-1722 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.7500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $293.71 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $119.88 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fludeoxyglucose F-18 Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Fludeoxyglucose F-18: FDA labeling (2021-11-03, NDC 24450-647), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fludeoxyglucose F-18 community threads and patient logs by age, biological sex, dosage, and treatment duration.